Alto Neuroscience, Inc. (NYSE:ANRO) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Alto Neuroscience, Inc. (NYSE:ANRO) have been given an average recommendation of “Moderate Buy” by the eight brokerages that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $35.1429.

A number of brokerages have recently issued reports on ANRO. BTIG Research upped their price objective on shares of Alto Neuroscience from $27.00 to $28.00 and gave the company a “buy” rating in a research note on Tuesday, February 17th. Wedbush dropped their target price on Alto Neuroscience from $22.00 to $21.00 and set a “neutral” rating for the company in a report on Thursday, April 2nd. Jefferies Financial Group restated a “buy” rating and set a $35.00 target price on shares of Alto Neuroscience in a report on Monday, March 16th. Wall Street Zen cut Alto Neuroscience from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Finally, JonesTrading dropped their target price on Alto Neuroscience from $49.00 to $44.00 and set a “buy” rating for the company in a report on Thursday, April 2nd.

Alto Neuroscience Price Performance

Shares of Alto Neuroscience stock opened at $22.52 on Tuesday. Alto Neuroscience has a 52-week low of $1.64 and a 52-week high of $25.17. The stock has a market capitalization of $719.35 million, a price-to-earnings ratio of -10.33 and a beta of 2.01. The company has a fifty day moving average of $19.40 and a 200-day moving average of $15.09. The company has a debt-to-equity ratio of 0.12, a quick ratio of 15.69 and a current ratio of 15.69.

Alto Neuroscience (NYSE:ANRO) last announced its quarterly earnings data on Monday, March 16th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.11. Equities research analysts expect that Alto Neuroscience will post -2.54 EPS for the current year.

Institutional Investors Weigh In On Alto Neuroscience

Several institutional investors have recently added to or reduced their stakes in ANRO. AQR Capital Management LLC purchased a new stake in Alto Neuroscience during the 1st quarter valued at $52,000. Torren Management LLC purchased a new stake in Alto Neuroscience during the 4th quarter valued at $62,000. Invesco Ltd. purchased a new stake in Alto Neuroscience during the 1st quarter valued at $67,000. Vanguard Personalized Indexing Management LLC boosted its position in Alto Neuroscience by 13.7% during the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 17,045 shares of the company’s stock valued at $69,000 after buying an additional 2,055 shares during the period. Finally, Bridgeway Capital Management LLC boosted its position in Alto Neuroscience by 85.9% during the 2nd quarter. Bridgeway Capital Management LLC now owns 54,100 shares of the company’s stock valued at $119,000 after buying an additional 25,000 shares during the period.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.